Search results
4 mar 2024 · The clinical manifestations and diagnosis of peripheral SpA; the classification of SpA; and the clinical manifestations, diagnosis, and treatment of axial SpA, PsA, reactive arthritis, arthritis associated with IBD, and SpA in children are discussed in more detail separately.
27 maj 2023 · For example, Humira (adalimumab) is a TNF inhibitor that is effective in people with peripheral spondyloarthritis. Peripheral spondyloarthritis is a complex condition that should be followed by a healthcare provider who specializes in the condition.
1 cze 2018 · Peripheral spondyloarthritis refers to spondyloarthritis with predominant peripheral (arthritis, enthesitis or dactylitis) involvement. Diagnosis can be challenging, particularly in the absence of SpA extra-articular manifestations such as uveitis, psoriasis or inflammatory bowel disease.
Learn more about HUMIRA® (adalimumab), a biologic treatment for adults with ankylosing spondylitis. See full prescribing and safety info, and BOXED WARNING.
30 lip 2012 · HUMIRA is indicated for the treatment of adults with severe axSpA without radiographic evidence of AS, but with objective signs of inflammation by elevated c-reactive protein (CRP) and/or MRI who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).
2 kwi 2024 · The treatment of peripheral SpA; the classification of SpA; and the clinical manifestations, diagnosis, and treatment axial SpA, PsA, reactive arthritis, arthritis associated with IBD, and SpA in children are discussed in more detail separately.
Objective: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). Methods: We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on ...
